Extracorporeal CO2 Removal Devices Market To Reach $137.2 Million By 2030

Extracorporeal CO2 Removal Devices Market Growth & Trends

The global extracorporeal CO2 removal devices market size is estimated to reach USD 137.2 million by 2030, expanding at a CAGR of 7.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological improvements changed extracorporeal techniques for CO2 removal in promising manner to avoid worsening respiratory acidosis and respiratory failure and to possibly shorten or prevent the duration of invasive mechanical ventilation in patients with exacerbation of asthma and COPD.

Extracorporeal CO2 removal devices is considered to be an efficient therapy for patients suffering from hypercapnia respiratory failure and may allow clinicians as well as healthcare professionals to improve lung protective ventilation. Extracorporeal CO2 removal devices can remove adequate CO2 to allow 50% reduction in alveolar minute ventilation resulting into substantial reduction in PaCO2. Hence, various advantages associated with extracorporeal CO2 removal devices is expected to augment the overall market progression.

Extracorporeal CO2 removal devices are effective, safe and feasible. The usage of extracorporeal CO2 removal devices in ventilation support has been suggested in clinical situations where they may be useful, including exacerbation of chronic obstructive pulmonary disease and acute respiratory distress syndrome. Increasing prevalence of COPD across the globe is predicted to accelerate the market growth. According to the British Lung Association, around 1.2 million people are living with diagnosed COPD in the U.K.

Several manufacturers in the market are focusing on developing technological advanced and innovative extracorporeal CO2 removal devices and strengthen its position in the market. For instance, In November 2015, Alung Technologies received Expedited Access pathway (EAP) from the FDA for its Hemolung Respiratory Assist System. In addition, in February 2016, Alung Technologies received USD 12 million financing from existing as well as new investors. This financing helped in commercialization of Hemolung Respiratory Assist System (RAS).

 Request a free sample copy or view report summary: Extracorporeal CO2 Removal Devices Market Report

Extracorporeal CO2 Removal Devices Market Report Highlights

• The extracorporeal CO2 machines segment dominated the market in 2024 with 52.4% of the market share and is expected to witness fastest growth due to their advanced ability to efficiently remove excess carbon dioxide from a patient’s bloodstream, particularly in critical care settings.

• The COPD segment is expected to hold a considerable market share in 2024 as ECCO2R devices may permit a decrease in respiratory rate and respiratory volume, resulting in elongated expiratory time that is better adapted to high expiratory time constant of respiratory system

• The venovenous segment are expected to grow at the fastest rate during the forecast period as it offers less invasiveness by evading arterial cannulation and has the potential for early mobilization of patients

• The hospital segment accounted for the largest revenue share of 46.7% in 2024 due to their ability to manage the complexity of critical care cases requiring such advanced respiratory support.

• The extracorporeal CO? removal devices market in North America is driven by the increasing clinical adoption across specialized care settings.

• This is attributable to the growing prevalence of COPD, ARDS, and increasing adoption of advanced extracorporeal CO2 removal devices

Extracorporeal CO₂ Removal Devices Market Segmentation

Grand View Research has segmented the global extracorporeal CO2 removal devices market based on product, application, access, end use, and region:

Extracorporeal CO2 Removal Devices Product Outlook (Revenue, USD Million, 2018 - 2030)

• Extracorporeal CO2 machines

• Disposables

• Others

Extracorporeal CO2 Removal Devices Application Outlook (Revenue, USD Million, 2018 - 2030)

• Acute Respiratory Distress Syndrome (ARDS)

• Chronic Obstructive Pulmonary Disease (COPD)

• Bridge To Lung Transplant

• Others

Extracorporeal CO2 Removal Devices Access Outlook (Revenue, USD Million, 2018 - 2030)

• Venovenous

• Arteriovenous

Extracorporeal CO2 Removal Devices End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers

• Clinics

• Others

Extracorporeal CO2 Removal Devices Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Norway

  • Denmark

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players of Extracorporeal CO2 Removal Devices Market

• Medtronic

• Getinge AB

• Xenios AG

• Medica S.P.A.

• Aferetica srl

• ALung Technologies, Inc.

• ESTOR S.P.A.

• Baxter

• X-COR Therapeutics